Managing Conflicts of Interest on Biopharma Boards
Every biopharma director carries competing interests into the boardroom. The investor-director whose fund holds a position in a company that is also a potential licensing partner. The scientific advisor who consults for a competitor. The independent director who sits on two boards operating in the same therapeutic area. The founder-CEO whose personal equity stake makes every strategic decision — sell the company now or continue to build — a simultaneously personal and fiduciary question.
Conflicts of interest are not aberrations in biopharma governance. They are structural features of an industry in which the same small population of investors, scientists, and executives circulates across a concentrated ecosystem of companies, funds, and institutions. The question is not whether conflicts exist — they almost always do — but whether the board has built a governance culture that identifies them honestly, manages them systematically, and prevents them from distorting the decisions that shape the company's future.
Most biopharma boards have a conflicts of interest policy. Far fewer have a governance culture in which that policy is applied with the rigor it requires.
What a Conflict of Interest Actually Is
A conflict of interest exists when a director has a personal, financial, or institutional interest that could — even if it does not — influence their judgment on a matter before the board in ways that are not aligned with the company's interests.
The crucial word is "could." A conflict does not require actual bias or demonstrable bad faith. It requires only that a reasonable person, aware of the interest, would question whether the director's judgment on the matter is fully independent. This is a lower threshold than most directors apply when assessing their own situations, which is why self-assessment of conflicts is so systematically unreliable. People tend to believe, with genuine sincerity, that their judgment is not affected by interests that clearly create a conflict — and they are often wrong.
This is not a character failing. It is a cognitive reality. The research on motivated reasoning is extensive: people process information in ways that are systematically shaped by their interests and prior commitments, often without awareness that this is happening. A director who genuinely believes their judgment on a licensing negotiation is unaffected by the fact that their fund is also an investor in the proposed licensee is not lying. They may simply be wrong about how their own mind works.
Effective conflict management does not rely on directors accurately self-assessing the degree to which their interests affect their judgment. It relies on structural processes — disclosure, independent review, recusal — that reduce the dependence on any individual's self-assessment.
The Spectrum of Conflicts
Not all conflicts are equal, and governance frameworks that treat them as a binary — you have a conflict or you do not — miss important nuance.
At one end are direct financial conflicts: a director who personally profits from a transaction the company is considering. A board member who holds equity in a company the board is evaluating as an acquisition target. An investor-director whose fund's position makes a particular exit structure significantly more valuable than an alternative that is better for other shareholders. These conflicts are the most straightforward to identify and the most clearly required to be managed through recusal.
In the middle are institutional conflicts: a director who represents a fund or institution whose interests are not identical to the company's, even in the absence of a specific transaction. An investor-director whose fund is approaching the end of its life and whose interest in a near-term exit may not align with the interests of other shareholders who would benefit from continued development. A corporate director who was placed on the board as part of a strategic partnership and whose primary loyalty is to the partner rather than to the company as an independent entity.
At the other end are relational and reputational conflicts: a director whose personal friendship with the CEO makes objective performance evaluation genuinely difficult. A director whose public positions on a scientific question are implicated in the board's assessment of the company's clinical data. A director who has a prior working relationship with a candidate being considered for a senior executive role, in either a positive or negative direction.
The middle and lower categories are the ones that governance policies most frequently handle inadequately. They are real conflicts — they create genuine risks to the independence of the affected director's judgment — but they do not fit neatly into the disclosure-and-recusal model designed for direct financial conflicts.
Disclosure: The First Obligation
The foundational obligation of any director with a potential conflict is disclosure. Before the board discusses any matter in which a director has a material interest — direct or indirect, financial or relational — that director is required to disclose the interest to the board.
In practice, disclosure cultures vary enormously. Boards with strong disclosure cultures have developed a norm in which directors surface potential conflicts proactively and early, before the matter reaches the point of decision. They do not wait to be asked. They do not engage in a private calculation about whether the conflict is significant enough to warrant disclosure. They err consistently on the side of transparency, understanding that the cost of unnecessary disclosure is a brief conversation and the cost of inadequate disclosure is a governance failure that can resurface with significant consequences.
Boards with weak disclosure cultures treat the obligation as a technicality — something to be satisfied with a formulaic statement at the opening of the relevant agenda item rather than a genuine commitment to transparency. In these environments, the disclosure norm is often enforced only when the conflict is obvious and undeniable, and the gray areas are consistently resolved in the direction of non-disclosure.
Building a strong disclosure culture requires the chair to model the behavior. When the chair discloses potential conflicts readily and without defensiveness — including conflicts that are minor and that will not result in recusal — they establish a norm that other directors observe and internalize. When the chair treats disclosure as something to be minimized, others follow that signal instead.
Recusal: When and How
Disclosure addresses the information problem. Recusal addresses the decision problem. When a director's conflict is material enough that their participation in the decision could compromise the integrity of the outcome, the appropriate governance response is for that director to recuse themselves from the relevant discussion and vote.
The standard for recusal is whether a reasonable person, aware of the conflict, would question the director's ability to exercise independent judgment on the matter. Applied honestly, this standard leads to recusal in a wider range of situations than most boards practice.
Recusal has several components that are sometimes individually practiced but rarely all practiced together. The recused director should absent themselves not only from the vote but from the substantive discussion. A director who participates fully in the debate that shapes other directors' views, then formally abstains from the vote, has not managed the conflict — they have performed the management of it while retaining their influence over the outcome. True recusal means leaving the room, or at minimum committing to silence during the discussion, for the duration of the matter from which they are recused.
The recused director should also not receive the materials prepared for that portion of the board's discussion. Information shared in preparation for a decision is part of the decision process, and a director who has reviewed the management recommendation, the financial analysis, and the supporting documentation before recusing themselves has already been influenced by material that should not have shaped their engagement with the matter.
The fact of recusal and the reason for it should be documented in the board minutes. This documentation serves a dual purpose: it creates a record that the governance process was followed, and it creates accountability for the pattern of recusal over time. A director who is recused from a significant proportion of the board's material decisions — because their conflicts are pervasive — is providing limited governance value in their current role, and the documentation of that pattern creates a basis for the larger conversation.
The Gray Areas
The hardest conflicts to manage are not the ones that clearly require recusal — those are navigable with a well-applied policy. The hardest ones are the structural and relational conflicts that are real but do not map cleanly onto the recusal framework.
An investor-director whose fund's interests diverge from the company's on the question of exit timing is in a genuinely conflicted position for every strategic discussion about the company's future. Recusing themselves from those discussions would render them largely unable to participate in the board's most important work. The realistic governance response is not recusal but disclosure, transparency about the institutional interest, and the active presence of independent directors who can provide a counterweight when the investor perspective becomes dominant.
A director with a prior negative experience with a management candidate being considered for a senior role is in a conflict that does not obviously require recusal but clearly requires disclosure. The board should know that the director's assessment of the candidate is colored by a prior relationship, so they can calibrate accordingly. Without that disclosure, the board may attribute the director's skepticism entirely to legitimate governance judgment when it is at least partly personal history.
A director whose public scientific positions are implicated in the board's evaluation of clinical data is in a subtle conflict that is almost never managed. The director who has publicly argued for a particular mechanism of action, or who has staked professional credibility on a specific therapeutic hypothesis, has an interest in the company's data confirming their prior position. This interest is real and should be named, even if the appropriate response is disclosure and heightened self-scrutiny rather than recusal.
Managing the gray areas requires a board culture that has moved beyond treating conflicts policy as a compliance exercise and has internalized the underlying purpose: ensuring that the people making decisions on behalf of the company's stakeholders are exercising judgment that is as independent as the governance structure can make it. That culture is not built through better policy language. It is built through the accumulated practice of directors who take the obligation seriously and who hold each other to it.
The Board's Responsibility for Systemic Conflicts
Individual conflict management — disclosure and recusal by individual directors — addresses specific instances. It does not address the systemic conflicts that are embedded in the board's composition.
A board dominated by investor-directors whose fund interests are broadly aligned with each other but not necessarily with minority shareholders or with the long-term interests of the scientific mission has a structural conflict problem that recusal cannot solve. A board that lacks independent directors with no material affiliations to the company, its investors, or its management has no constituency whose primary obligation is to the company's interests as a whole.
This is ultimately a composition question, and it is one that the board's governance or nominating function — where such a function exists — should address explicitly. The assessment of board composition should include not only the skills and expertise represented but the degree to which the director population, taken as a whole, is capable of exercising governance that is genuinely independent of any particular institutional interest.
In early-stage venture-backed biopharma, the practical constraints on independent director recruitment are real. Compensation is modest, the company is unknown, and the governance obligations are significant. But the effort to recruit directors with genuine independence — scientists with no fund affiliations, executives with no competing portfolio conflicts, governance professionals who bring institutional knowledge of good practice — is an investment in governance quality that compounds over the life of the company.
The board that has built that capacity will handle conflicts better at every level — individual, relational, and structural — because it has a foundation of independence from which the governance function can actually operate.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on governance structure and board dynamics across life sciences and advanced materials companies.